News from Relmada Therapeutics, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 28, 2017, 08:00 ET Relmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the Dextromethadone Scientific Advisory Board for its Depression Program

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous...


Jun 21, 2017, 08:00 ET Dr. Ottavio Vitolo Appointed Executive Clinical Advisor at Relmada Therapeutics

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS)...


Jun 15, 2017, 08:30 ET Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS)...


Apr 13, 2017, 08:00 ET Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS)...


Feb 15, 2017, 08:00 ET Relmada Therapeutics to Participate in the 2nd Annual Disruptive Growth & Healthcare Conference

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS)...


Feb 13, 2017, 08:30 ET Relmada Therapeutics to Participate in BIO CEO and Investor Conference

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS)...


Jan 25, 2017, 17:41 ET Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS)...


Jan 24, 2017, 16:30 ET Relmada Therapeutics to Provide an Update on the Development Plan for LevoCap ER

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS)...


Jan 05, 2017, 08:30 ET Relmada Therapeutics to Present at Biotech Showcase 2017

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS)...


Nov 29, 2016, 08:30 ET Relmada Therapeutics to Present at LD Micro "Main Event" Investor Conference

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS)...


Oct 27, 2016, 08:30 ET Relmada Therapeutics to Present at the Sidoti & Company Fall 2016 Emerging Growth Convention

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS)...


Oct 19, 2016, 08:30 ET Relmada Therapeutics Announces Issuance of Key U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression and Other Psychiatric Symptoms

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS)...


Oct 06, 2016, 08:30 ET Relmada Therapeutics to Present at the 15th Annual BIO Investor Forum

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS)...


Sep 28, 2016, 08:30 ET Relmada Therapeutics' Chief Scientific Officer Dr. Richard Mangano to Speak about d-Methadone as a Potential Rapid Acting Antidepressant at Neuro Advance Boston

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system...


Sep 22, 2016, 08:00 ET Relmada Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system...


Sep 20, 2016, 08:30 ET Relmada Therapeutics to Present at the 2016 Aegis Growth Conference

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS)...


Sep 14, 2016, 08:30 ET Relmada Therapeutics Files Amended Complaint Against Laidlaw and Its Principals, Matthew Eitner and James Ahern

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS)...


Sep 12, 2016, 08:30 ET Pharmaceutical Industry Leader Ronald M. Burch Joins Relmada Therapeutics Advisory Team

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system...


Sep 07, 2016, 08:30 ET Relmada Therapeutics to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system...


Jul 06, 2016, 08:30 ET Relmada Therapeutics Secures First European Patent Covering LevoCap ER

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system...


Jun 27, 2016, 08:30 ET Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system...


Jun 07, 2016, 08:30 ET Relmada Therapeutics' d-Methadone Receives Orphan Drug Designation for Management of Postherpetic Neuralgia

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...


Jun 01, 2016, 08:30 ET Relmada Therapeutics to Present at the LD Micro Invitational Conference

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...


May 04, 2016, 08:30 ET Relmada Therapeutics Announces Results of In Vivo Study Showing d-Methadone has Antidepressant-like Effects

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today...


Apr 28, 2016, 08:30 ET Relmada Therapeutics to Present at the Joseph Gunnar "Pioneers 2016" Conference

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced...